Showing results (1671-1680 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|July 12, 2002
Economic benefits of amlodipine treatment in patients with coronary artery diseaseRoman Casciano, John J Doyle, John Chen, et al.Pharmacoeconomics|May 31, 2002
A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environmentDavid L Veenstra, Scott D Ramsey, Sean D SullivanPharmacoeconomics|May 31, 2002
Applications of economic models in healthcare: the introduction of pioglitazone in SwedenFreddie HenrikssonPharmacoeconomics|May 8, 2002
Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosisHeini Salo, Markku PekurinenPharmacoeconomics|August 7, 2002
Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use dataBo Standaert, Janet Goldstone, Z John Lu, et al.Pharmacoeconomics|August 31, 2002
Prospective study designs in outcomes research: the case of migraineElizabeth A Rothermich, Meryl I Brod, Warren H Schonfeld, et al.Pharmacoeconomics|August 31, 2002
Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac deathMarian A Spath, Bernie J O'BrienPharmacoeconomics|August 31, 2002
Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophiliaAlexander H Miners, Caroline A Sabin, Keith H Tolley, et al.Pharmacoeconomics|September 19, 2002
UK department of health guidance on prescribing for impotence following the introduction of sildenafil: potential to contain costs in the average health authority districtMartin Ashton-Key, Michael Sadler, Byron Walmsley, et al.Pharmacoeconomics|July 18, 2001
An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The NetherlandsR M Herings, O H KlungelPageof 336